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OBJECTIVES: To evaluate the cost-consequence of LVP/r
compared with NFV in treating antiretroviral (ARV)
naïve HIV patients. METHODS: A decision tree model
was developed based on the Department of Health and
Human Services (DHHS) guidelines and the survey of
HIV treating physicians. The model was used to reana-
lyze the ABT-M98-863 pivotal clinical trial data submit-
ted to FDA/EMEA, a randomized phase III study of LVP/r
vs. NFV plus d4T/3TC in 653 ARV naïve HIV patients.
Therapeutic failure was deﬁned as 2 successive (4 weeks
apart) viral loads (VL) >400 copies/ml. In the model,
therapeutic responders continued with their initial treat-
ment, while failures received drug resistance tests and
additional monitoring. Failures who developed drug
resistance switched to a 2PIs + 2NRTIs regimen, while
others stayed in the PI + 2NRTIs regimen class. A
maximum of 1 therapy switch was allowed. Failures were
at risk for AIDS events determined by CD4 count and VL.
Cost analysis in 2002 U.S. dollars was performed from a
third party payer’s perspective. One-way sensitivity analy-
sis tested the robustness of the assumptions. RESULTS:
The model showed that after 60 weeks of therapy, com-
pared to NFV, 22.1% more patients who started on LVP/r
remained as responders, yielding a net savings of
$1,454.14 per patient. Reduced treatment costs for
therapy failures and AIDS events were the main contri-
butions to the net savings. In sensitivity analysis, when
the VL threshold for therapeutic failure was set at 50,
1,000, or 5,000 copies/ml, cost savings remained at
$1,520.15, $1,233.52, and $1,062.26, respectively. When
the regimen for all failures was changed to 2PI + 2NRTIs,
PI + NNRTI + 2NRTIs, or PI + 2NRTIs, the estimated
savings changed to $2,704.38, $1,928.46, and $838.35,
respectively. CONCLUSIONS: The results suggest that if
treatment guidelines are applied in the management of
ARV naïve HIV patients, LVP/r may reduce the number
of patients switching regimens and consequently may
decrease total costs when compared with NFV.
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OBJECTIVE: The present study was carried out to 
evaluate the economic burden of chronic hepatitis B
(CHB) and its complications, and to evaluate the clinical
and economic beneﬁts of treatment of CHB patients with
lamivudine for one year in Shanghai, China. METHODS:
The components of the economic burden of disease
included direct medical costs, non-medical costs and 
indirect work related costs per patient per year in CHB
patients (n = 634), those who had progressed to com-
pensated hepatocirrhosis (n = 294), decompensated hepa-
tocirrhosis (n = 231) and hepatocellular carcinoma (n =
236), respectively. The direct medical costs per patient per
year were calculated according to the mean expenses and
utilisation rate for each outpatient visit and hospitalisa-
tion. The direct non-medical costs were estimated based
on expenses for nutrition products and transportation.
Mean indirect costs were calculated using average time
lost from work in one year. Clinical and economic 
beneﬁts of CHB treatment with lamivudine were esti-
mated using cost data from the burden of illness study in
Shanghai and seroconversion rate data in Asian patients
and cirrhosis progression rates from lamivudine clinical
trials. RESULTS: Treatment of patients with ALT >
2xULN with lamivudine for 1 year is estimated to result
in net total cost savings of US$51 per patient. CON-
CLUSION: Chronic hepatitis B infection not only com-
promises the patient’s normal daily activities, but also
imposes a signiﬁcant economic burden on patients and
their families. By reducing the rate of progression to cir-
rhosis, treatment of CHB patients with lamivudine for
one year can result in overall net cost savings.
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OBJECTIVES: To evaluate health outcomes and costs to
the health care payer of treating inﬂuenza in an at-risk
population with anti-virals (oseltamivir). METHODS:
Based on clinical trial data and data from the literature a
microsimulation model incorporating ﬁrst- and second-
order Monte Carlo simulation was developed. The under-
lying clinical pathway predicts morbidity and mortality
due to inﬂuenza and its speciﬁed complications. Health
outcomes (QALYs, days to return to normal activity) and
costs were estimated for events in the model. The model
compares various scenarios, which are deﬁned by alter-
native treatment schemes within deﬁned populations and
other parameters. Robustness of the results is tested 
by probabilistic and univariate sensitivity analysis. The
model is used to simulate the results for an at-risk popu-
lation in the UK comparing Oseltamivir with usual care.
RESULTS: Treatment with Oseltamivir within 48 hours
results in reduced morbidity, which translates into faster
recovery and faster return to normal activities (by 5.28
days). Lower morbidity and mortality make this a cost-
effective intervention from a health care payer perspec-
tive with Oseltamivir being dominant compared to usual
care in both cost-effectiveness and cost-utility analysis.
CONCLUSION: Treatment with Oseltamivir is effective
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in terms of health outcome as well as in terms of cost for
high-risk patients from the perspective of the individual
patient as well as of the health care payer. However, this
effect is sensitive to time of treatment start, diagnostic cer-
tainty as well as rates for hospitalisation, complication
and mortality.
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OBJECTIVE: Pneumococcical vaccine is an affective pre-
ventive intervention to prevent pneucoccical pneumonia.
In this study, cost-effectiveness of pneumococcical vacci-
nation (23 serotipes) strategies in individuals aged 5 or
more years was assessed. METHODS: Cost-effectiveness
was measured in terms of cost per life year gained (LYG),
comparing net programme costs and effectiveness. The
net programme cost was calculated from vaccinating
costs, assuming 70% compliance, less reduced health
costs from pneumococcical pneumonia achieved with the
programme. Vaccination costs were calculated taking into
account a cost of €11,51 per vaccine. Costs and beneﬁts
were estimated for 1996 using a 5% discount rate.
RESULTS: A cost-effectiveness ratio of €9.023,27 per
LYG was obtained for the universal vaccination of the
population. The cost-effectiveness ratio was €113.177,12
per LYG in individual aged 5–24 years, €19.482,51 per
LYG in those aged 25–44 years, €7.122,80 per LYG in
those aged 45–64y < 0 in those aged >64 years. In the
age group of >64 years, disease costs reduced were higher
than vaccination costs, with a savings/costs ratio of 1,58.
Results of cost-effectiveness analysis were sensitive to the
vaccine price, vaccine efﬁcacy and the percentage of pneu-
monias caused by S. pneumoniae, being less sensitive to
health costs from pneumococcical pneumonia, hospital-
ization rate in patients with a community acquired pneu-
monia and vaccination compliance. CONCLUSION:
Results obtained in this study shows that pneumococci-
cal vaccination should be a priority preventive interven-
tion in individuals aged >64 and 45–64 years.
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OBJECTIVES: For many diseases, a small number of
complicated cases accounts for the main part of the costs.
Our aim was to investigate the relevance of complications
for the overall costs of varicella in Germany in order 
to assess whether vaccination strategies targeting at risk
groups, e.g. adolescents, have the potential to sub-
stantially reduce the economic burden of varicella.
METHOD: A decision-analytic model, the Economic
Varicella VaccInation Tool for Analysis (EVITA), was
used to analyze epidemiological and economic effects of
varicella over a period of 30 years as varicella incidence
ﬂuctuates over time and, thus, a typical cost of illness
study performed in one year might provide biased esti-
mates of overall costs. Input data on the epidemiology 
of varicella and its complications as well as the respec-
tive resource use were derived from two large surveys.
RESULTS: Complications occur in 5.7% of the annual
average of 739,000 cases. Overall annual costs are €187.5
million from the societal and €78 million from the payers’
perspectives. From the payers’ (societal) perspective
32.0% (24.7%) of the overall costs can be attributed 
to complications. Complications account for 53.8%
(53.3%) of the direct medical costs and 15.5% (18.3%)
of the indirect costs. When complications occur, inpatient
care (67.7%) from the payers’ and work loss (60.9%)
from the societal perspectives are the main cost drivers 
of complications. Pneumonia accounts for the majority 
of the costs of complications. For uncomplicated 
courses of varicella, the indirect costs of work loss are 
the major cost factor. CONCLUSIONS: Complications
account for a disproportionate part of overall disease
costs. However, uncomplicated courses account for the
vast majority of costs. Vaccination strategies targeting
only on risk groups with high risks of complications
might therefore fail to substantially reduce the consider-
able economic burden of varicella.
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OBJECTIVE: In Japan, measles vaccine coverage is lower
than 80% nationwide. As a result, the number of measles
case is estimated about 100,000–200,000 a year. In this
study, we performed cost-beneﬁt analysis between the
cost of vaccination and the cost of treatment of measles.
Although cost effectiveness analysis including cost-beneﬁt
analysis of vaccination is extensively performed (e.g.
inﬂuenza), it is not carried out concerning measles at all.
This research is unique in this point of view. METHODS:
We conducted chart investigation of 291 measles patients
(171 outpatient cases and 120 hospitalization cases) in
one hospital from July 1997 to September 2001. Among
them, medical expenses were calculated about 121
samples of outpatients and 112 inpatients which are 
considered to be appropriate for the contents of medical
treatment. At the same time, we estimated opportunity
